Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide vs Placebo in Low Risk MDS with 5q Deletion
NCT01243476Phase 3Completed
- Sponsor
- Fundación General de la Universidad de Salamanca
- Start
- Jan 2010
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of lenalidomide in myelodysplastic syndrome (MDS), sponsored by Fundación General de la Universidad de Salamanca. Started Jan 2010; status: completed.
02
Drugs
lenalidomide
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01243476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01243476.